Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:18 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9115

Shown on this page

Current sort

Institutions in Tampa

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Moffitt Cancer Center

Live official records

Open in full search

Conditions: Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Tampa, Florida • Iowa City, Iowa • Chapel Hill, North Carolina + 3 more

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions: Carboplatin, Cisplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Proton Beam Radiation Therapy; Drug · Procedure · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 79 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 178
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 128 more

Conditions: Crohn's Disease
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 34
States / cities: Colorado Springs, Colorado • Kissimmee, Florida • Miami, Florida + 26 more

Conditions: Myelofibrosis (MF)
Interventions: Not applicable- observational study; Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Tampa, Florida • Columbus, Ohio + 2 more

Conditions: Crohn's Disease
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 127
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 107 more

Conditions: Colitis Ulcerative
Interventions: SAR441566, SAR441566 matching Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 19
States / cities: Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more

Conditions: Refractory Metastatic Colorectal Cancer
Interventions: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone; Drug
Lead sponsor: Delcath Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Duarte, California • Santa Monica, California • Miami, Florida + 6 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Psoriatic Arthritis
Interventions: Tulisokibart, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Sun City, Arizona • Tucson, Arizona • Riverside, California + 15 more

Conditions: AML, Adult, MDS
Interventions: Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine, Azacitadine (AZA); Drug
Lead sponsor: Stelexis BioSciences; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Duarte, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Early Alzheimer's Disease
Interventions: MK-2214, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 36
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 32 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 8
States / cities: La Jolla, California • Tampa, Florida • Atlanta, Georgia + 2 more

Clinical trials in Tampa, Florida

Filter and sort this location

Institutions in Tampa

Live official records

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Pacritinib Effectiveness in Real-world Settings

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer